Phase 1 Clinical Trials Program

Karmanos’ Phase 1 Clinical Trials Multidisciplinary Team conducts clinical research studies with new, investigational cancer drugs.

Phase 1 trials are the first stage of clinical trials in the careful process of developing new cancer treatments. A typical Phase 1 clinical trial evaluates how a new drug should be given, either orally or injected into the blood, how often, and what dosage is safe. A Phase I trial is often the first time a drug has been given to human, or the first time a new drug has been given to a human in combination with another standard cancer treatment.

Evaluation and Diagnosis

Each patient receives personal attention from the Phase 1 Team. All patients considered for a Phase 1 clinical trial must go through an initial screening consultation to determine if they are eligible for a research study and if a clinical trial is their best treatment option.

Patient safety and care are our top priorities. Phase 1 Team physicians, nurse practitioners and physician assistants monitor patients carefully for any changes in their condition and will maintain close contact with referring physicians. Patients may opt-out of a clinical trial at any time.

Innovative, Individualized Care

Here’s what patients can expect from our Phase 1 Clinical Trials Multidisciplinary Team:

  • A passionate, caring, expert team, giving the best chance of success.
  • A collaborative approach that considers all available treatment options.
  • A carefully constructed treatment plan designed to achieve the best possible outcome.
  • Respectful, compassionate care that is responsive to the emotional needs and lifestyle of a patient.
  • Proactive, timely communication with patients, caregivers and the referring physician.

Appointment Information

Request an Appointment Online Request an Appointment By Phone

The Latest From Karmanos Cancer Institute

News

U CAN-CER VIVE Gives $450K+ to Karmanos Cancer Institute for Continued Research in Using Radiofrequency to Treat Cancer

The Barbara Ann Karmanos Cancer Institute has been awarded $459,010 for continued research in treating cancers with radiofrequency electromagnetic...

Read More

New Grant Allows Karmanos Researchers to Continue Research Using Electromagnetic Radiofrequency Fields to Treat Fibrolamellar Carcinoma

A Barbara Ann Karmanos Cancer Institute and Wayne State University research team has received a $49,500 grant to research a rare cancer. The grant...

Read More

IN THE NEWS – New Hope for Myeloma Patients: Karmanos Advances Treatment and Survival

Telegram News Craig Cole, M.D. , malignant hematologist and member of the  Hematology Oncology  and  Multiple Myeloma and Amyloidos...

Read More
News

WDET | Doctor Says HPV Vaccine and Routine Screenings Aid Against Cervical Cancer

Listen Now

WWJ | World Cancer Day

Listen Now

WWJ | Ribbon Cutting Held for New Karmanos Cancer Center in Dearborn That Strives to Improve Access to Treatment, Clinical Trials

Listen Now